The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessAbstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citationHakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., Haroutunian, V., & Fienberg, A. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081071198 · Cited by 1,192 · cited 3×
“(Hakak et al., 2001) and a quantitative PCR study of the Stanley collection have confirmed the robust reduction in the expression of GCPII in prefrontal cortex in schizophrenia (Huffacker et al.”
BackgroundResultInfluentialRole of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity
Liu, L., Wong, T. P., Pozza, M. F., Lingenhoehl, K., Wang, Y., Sheng, M., Auberson, Y. P., & Wang, Y. T. (2004) · Science · doi:10.1126/science.1096615 · Cited by 1,102 · cited 1×
“Thus, the NMDAR is viewed as central to the mechanisms of synaptic plasticity (Liu et al., 2004).”
BackgroundGABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082 · cited 1×
“…and DNA chip array methods, have confirmed the reduction in the presynaptic markers for GABAergic inter-neurons in subsectors of the hippocampal formation and in the intermediate layers of the prefrontal and cingulate cortex [for reviews, (Benes and Berretta, 2001; Lewis et al., 2004)].”
MethodNeuregulins: functions, forms, and signaling strategies
Falls, D. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00102-7 · Cited by 1,071 · cited 6×
“, 1998), Neuregulin (Falls, 2003), Regulator of G-protein Signaling 4 (RGS4; Williams et al.”
BackgroundInfluentialRessler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063 · cited 11×
“Furthermore, functional brain imaging studies now provide evidence that D-cycloserine enhances left superior temporal gyrus activation in schizophrenic subjects performing a memory task and that the response correlates significantly with the reduction in negative symptoms (YurgelunTodd et al., 2005).”
BackgroundResultInfluentialA Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034 · cited 4×
“However, with the possible exception of clozapine in a subgroup of patients (Meltzer, 1997; Davis et al., 2003), the typical and second generation antipsychotics leave most patients substantially disabled due to negative symptoms and cognitive impairments.”
BackgroundMethodInfluentialThe Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020 · cited 2×
“unique effects on a subpopulation of schizophrenic patients that respond poorly to other antipsychotics (Meltzer and McGurk, 1999).”
BackgroundStudy of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921 · cited 2×
“that was difficult to distinguish from schizophrenia (Luby et al., 1959; Itil et al., 1967).”
BackgroundAtypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899 · cited 1×
“All current antipsychotics exert their effects primarily by blocking D2 dopamine receptors (Snyder, 1981; Seeman, 2002).”
BackgroundBenes, F. M. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350036005 · Cited by 890 · cited 2×
“Benes pioneered the investigation of the cellular pathology of corticolimbic GABAergic inter-neurons in schizophrenia (Benes et al., 1991).”
BackgroundRegionally Localized Thinning of the Cerebral Cortex in Schizophrenia
Kuperberg, G. R., Broome, M. R., McGuire, P. K., David, A. S., Eddy, M., Ozawa, F., Goff, D., West, W. C., Williams, S. C. R., van der Kouwe, A. J. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.878 · Cited by 843
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., La Rosa, P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 829
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811 · cited 1×
“Both serine racemase, that synthesizes D-serine (SR), and D-amino acid oxidase (DAAO), which catabolizes D-serine, are localized to astrocytes (Schell, 2004; Wolosker et al., 1999; Kirkpatrick et al., 2001; Harrison and Weinberger, 2004).”
BackgroundRegionally localized thinning of the cerebral cortex in schizophrenia
Kuperberg, G. R., Broome, M., McGuire, P. K., David, A. S., Eddy, M., Ozawa, F., Goff, D., West, W. C., Williams, S. R., van der Kouwe, A. W., et al. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)81127-1 · Cited by 759 · cited 2×
“Cortical atrophy (Kuperberg et al., 2003) and loss of dendritic spines (Hill et al., in press) observed in schizophrenia may be predictable consequences of the persistent loss of the trophic effects of NMDAR activity.”
BackgroundA decrease of reelin expression as a putative vulnerability factor in schizophrenia
Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15718 · Cited by 753 · cited 1×
“These studies show compensatory upregulation of postsynaptic GABAA receptors in the very regions associated with downregulation of presynaptic GABAergic markers (Hanada et al., 1987; Benes et al., 1996; Impagnatiello et al., 1998; Volk et al., 2002).”
BackgroundKetamine: an update on the first twenty-five years of clinical experience
Reich, D. L., & Silvay, G. (1989) · Canadian Journal of Anaesthesia · doi:10.1007/bf03011442 · Cited by 708 · cited 1×
“Notably, children are relatively resistant to this side-effect, mirroring the developmental trajectory for psychosis in schizophrenia (Reich and Silvay, 1989).”
BackgroundD-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674 · cited 1×
“Lahti et al. (2001) demonstrated that subjects with remitted schizophrenia were quite sensitive to the psychotomimetic effects of infused ketamine and that it brought forward symptoms that were unique to the individual.”
BackgroundJavitt, D. C., Steinschneider, M., Schroeder, C. E., & Arezzo, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11962 · Cited by 662 · cited 1×
“Furthermore, his research in monkeys indicates the central role of NMDAR in mismatch negativity paradigms for ERPs (Javitt et al., 1994, 1996).”
BackgroundA Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651 · cited 4×
“toms correlates with the atrophic changes in the brain (Kirkpatrick et al., 2001).”
BackgroundInfluentialImmunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies
Simmons, M. L., Frondoza, C. G., & Coyle, J. T. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90101-s · Cited by 626 · cited 1×
“Immunocytochemical studies have demonstated that NAA is particularly enriched in the projecting glutamatergic neurons in these regions (Simmons et al., 1991).”
BackgroundSelf-citationKetamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604 · cited 1×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundGenes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Goldberg, T. E., Egan, M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., Goldman, D., & Weinberger, D. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.889 · Cited by 583 · cited 3×
“These include COMT (Goldberg et al., 2003), Dysbindin (Blake et al., 1998), Neuregulin (Falls, 2003), Regulator of G-protein Signaling 4 (RGS4; Williams et al., 2004), Disrupted In Schizophrenia 1 (DISC1; Cannon et al., 2005), metabotrophic glutamate receptor3 (GRM3; Egan et al., 2004) and G-72 (Chumakov et al., 2002).”
BackgroundUmbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 583
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571 · cited 5×
“Thus, we demonstrated the robust effects of DD-serine on the symptoms of schizophrenia (Tsai et al., 1998) 4 years before the first genetic evidence that it may be an important risk pathway for schizophrenia appeared (Chumakov et al., 2002).”
BackgroundMethodInfluentialSelf-citationImpaired recruitment of the hippocampus during conscious recollection in schizophrenia
Heckers, S., Rauch, S., Goff, D., Savage, C., Schacter, D., Fischman, A., & Alpert, N. (1998) · Nature Neuroscience · doi:10.1038/1137 · Cited by 570 · cited 1×
“In PET studies, Heckers et al. (1998) were able to dissociate activations in the dorsolateral prefrontal cortex and the hippocampus during verbal episodic memory retrieval in schizophrenics (Heckers et al., 1998).”
BackgroundEvidence for Abnormal Cortical Functional Connectivity During Working Memory in Schizophrenia
Meyer-Lindenberg, A., Poline, J.-B., Kohn, P. D., Holt, J. L., Egan, M. F., Weinberger, D. R., & Berman, K. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1809 · Cited by 507 · cited 2×
“affect primarily glutamatergic afferents (Meyer-Lindenberg et al., 2001).”
BackgroundImpaired recruitment of the hippocampus during conscious recollection in schizophrenia
Heckers, S., Rauch, S. L., Goff, D., Savage, C. R., Schacter, D. L., Fischman, A. J., & Alpert, N. M. (1998) · NeuroImage · doi:10.1016/s1053-8119(18)30930-3 · Cited by 492
Treatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 491 · cited 4×
“The therapeutic effects of clozapine on negative symptoms in responsive patients can evolve over months (Meltzer, 1997), suggesting that the effects reflect a gradual reparative process for this antipsychotic that may have unique effects on NMDAR.”
BackgroundInfluentialHashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 490 · cited 1×
“…and reduces positive symptoms in patients with chronic schizophrenia, who are receiving concurrent typical antipsychotic medications (Tsai et al., 1998; Heresco-Levy et al., 2002) and (2) that serum and CSF levels of D-serine are reduced in schizophrenic subjects (Hashimoto et al., 2003, 2005).”
BackgroundEfficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487 · cited 1×
“The findings with the full agonist glycine have been replicated in two additional clinical trials (Heresco-Levy et al., 1999; Javitt et al., 2001).”
ResultKynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L. H., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 471 · cited 2×
“Kynurenic acid levels are also elevated in the CSF of living patients with schizophrenia (Erhardt et al., 2001; Nilsson et al., 2005).”
BackgroundNMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · cited 5×
“be 10-fold more sensitive to the inhibitory effects of amino-phosphono-valeric acid (APV) and NAAG than adjacent pyramidal cells (Grunze et al., 1996).”
BackgroundResultInfluentialAbnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455 · cited 8×
“dase II (GCPII), which catabolyzes NAAG to NAA and glutamate, was reduced in frontal cortex, hippocampus and temporal cortex in a postmortem comparison of schizophrenic subjects to suitable controls (Tsai et al., 1995).”
BackgroundInfluentialTalbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., Hahn, C.-G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420425 · Cited by 455 · cited 1×
“The expression of dysbindin is reduced in prefrontal cortex and hippocampus in schizophrenia (Talbot et al., 2004; Weickert et al., 2004).”
BackgroundBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436 · cited 2×
“In a large parallel placebo-controlled trial, Goff et al. (1999) replicated the effects of D-cycloserine on negative symptoms in chronic schizophrenics receiving typical antipsychotics but not the cognitive effects (Goff et al., 1999).”
BackgroundResultSelf-citationNeuroimaging studies of the hippocampus in schizophrenia
Heckers, S. (2001) · Hippocampus · doi:10.1002/hipo.1068 · Cited by 420 · cited 1×
“…studies over the last two decades have provided compelling evidence that schizophrenia is associated with enlargement of the lateral ventricles and the loss of volume in the prefrontal cortex, the temporal cortex, the hippocampus, the amygdala and the thalamus (Heckers, 2001; Yamasue et al., 2004).”
BackgroundBerman, K. F. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020032005 · Cited by 417 · cited 2×
“of the Wisconsin Card Sort Task, which schizophrenic subjects perform poorly, in functional brain imaging studies dramatically enhanced the evidence of hypofrontality in schizophrenic subjects as compared to controls (Berman et al., 1986).”
BackgroundVariation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia
Egan, M. F., Straub, R. E., Goldberg, T. E., Yakub, I., Callicott, J. H., Hariri, A. R., Mattay, V. S., Bertolino, A., Hyde, T. M., Shannon-Weickert, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405077101 · Cited by 416 · cited 4×
“NAAG is a potent and specific agonist at the mGluR3 receptor (Wroblewska et al., 1997; Bischofberger and Schild, 1996), which gene has been associated with the risk for schizophrenia (Egan et al., 2004).”
BackgroundInfluentialModulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411 · cited 2×
“(NFPS) with its sub-nanomolar affinity for GlyT1 to study the impact of inhibiting GlyT1 on glutamatergic neurotransnmission in the CA1 sector of the acute hippocampal slice preparation (Bergeron et al., 1998).”
BackgroundMethodSelf-citationWoo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411 · cited 2×
“…hypofunction and GABAergic interneurons was further strengthened with the postmortem findings from a dual in situ hybridization study that showed a reduced number of GAD67 expressing neurons that co-express NR2A in the prefrontal cortex in schizophrenics as compared to controls (Woo et al., 2004).”
ResultA subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia
Woo, T.-U., Whitehead, R. E., Melchitzky, D. S., & Lewis, D. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5341 · Cited by 410 · cited 2×
“sented evidence for the loss of GABAergic chandelier cell terminals (“cartridges”) on pyramidal initial axon segments (Woo et al., 1998; Volk et al., 2001).”
BackgroundLisman, J. E., & Otmakhova, N. A. (2001) · Hippocampus · doi:10.1002/hipo.1071 · Cited by 401 · cited 1×
“…to the dopamine hypothesis because results thus far point to important interactions between dopamine receptors and NMDAR in critical brain regions such as the hippocampus (Lisman and Otmakhova, 2001) and between glutamatergic afferents and subcortical dopaminergic nuclei (Lisman and Grace, 2005).”
BackgroundKegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377 · cited 2×
“Schizophrenic subjects exhibit enhanced release of forebrain dopamine with an amphetamine challenge as measured by 125I-IBZM displacement with PET scanning; low dose ketamine produces the same effect in normal volunteers (Kegeles et al. 2000).”
BackgroundEarly-stage visual processing and cortical amplification deficits in schizophrenia
Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., Revheim, N., Silipo, G., & Javitt, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.5.495 · Cited by 362 · cited 1×
“Javitt has demonstrated that schizophrenic subjects have ERP abnormalities not only at cognitive levels but also at perceptual levels (Butler et al., 2005).”
BackgroundWeickert, C. S., Straub, R. E., McClintock, B. W., Matsumoto, M., Hashimoto, R., Hyde, T. M., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.6.544 · Cited by 352 · cited 1×
“The expression of dysbindin is reduced in prefrontal cortex and hippocampus in schizophrenia (Talbot et al., 2004; Weickert et al., 2004).”
BackgroundEvidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia
Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., Ozaki, N., Taguchi, T., Tatsumi, M., Kamijima, K., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh280 · Cited by 349 · cited 1×
“Dysbindin is concentrated the presynaptic glutamatergic terminals where it interacts with SNAP and synapsin 1 and modulates vesicular release of glutamate (Numakawa et al., 2004).”
BackgroundTsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342 · cited 4×
“fold persistence of the memory of the platform’s location in the Morris water maze (Tsai et al., 2004).”
BackgroundInfluentialAdler, C. M., Malhotra, A. K., Elman, I., Goldberg, T., Egan, M., Pickar, D., & Breier, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337 · cited 1×
“Adler et al. (1999) using similar methods found that ketamine induced a thought disorder similar to that observed in schizophrenia.”
ResultCannon, T. D., Hennah, W., van Erp, T. G. M., Thompson, P. M., Lonnqvist, J., Huttunen, M., Gasperoni, T., Tuulio-Henriksson, A., Pirkola, T., Toga, A. W., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1205 · Cited by 337 · cited 2×
“In Schizophrenia 1 (DISC1; Cannon et al., 2005), metabotrophic glutamate receptor3 (GRM3; Egan et al.”
BackgroundMatsui, T., Sekiguchi, M., Hashimoto, A., Tomita, U., Nishikawa, T., & Wada, K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010454.x · Cited by 334 · cited 2×
“than glycine (Matsui et al., 1995) and exhibits a long half-life in cortex upon peripheral administration (Hashimoto and Chiba, 2004).”
BackgroundLiu, H., Heath, S. C., Sobin, C., Roos, J. L., Galke, B. L., Blundell, M. L., Lenane, M., Robertson, B., Wijsman, E. M., Rapoport, J. L., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042700699 · Cited by 323 · cited 2×
“D-Amino acid oxidase (DAAO) and proline oxidase (Liu et al., 2002), both of which also affect glutamatergic neurotransmission, have also received support as candidate risk genes for schizophrenia (Kirov et al., 2005) G72, a gene of recent evolutionary appearance, encodes a protein that activates…”
BackgroundSchumacher, J., Abon Jamra, R., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A. C. J., Tullius, M., Kovalenko, S., Van Den Bogaert, A., Maier, W., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001421 · Cited by 312 · cited 1×
“…the risk for bipolar disorder (Chumakov et al., 2002; Hattori et al., 2003; Addington et al., 2004; Chen et al., 2004; Korostishevsky et al., 2004; Schumacher et al., 2004; Wang et al., 2004; Korostishevsky et al., 2006), One study reported increased expression of G72 in prefrontal cortex…”
BackgroundN‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells
Wroblewska, B., Wroblewski, J. T., Pshenichkin, S., Surin, A., Sullivan, S. E., & Neale, J. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010174.x · Cited by 298 · cited 3×
“NAAG is a potent and specific agonist at the mGluR3 receptor (Wroblewska et al., 1997; Bischofberger and Schild, 1996), which gene has been associated with the risk for schizophrenia (Egan et al., 2004).”
BackgroundGomeza, J., Hülsmann, S., Ohno, K., Eulenburg, V., Szöke, K., Richter, D., & Betz, H. (2003) · Neuron · doi:10.1016/s0896-6273(03)00672-x · Cited by 294 · cited 2×
“icity but rather because of respiratory failure due to excessive stimulation of brainstem inhibitory glycine receptors (Gomeza et al., 2003).”
BackgroundBenes, F. M., Vincent, S. L., Marie, A., & Khan, Y. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00328-4 · Cited by 274 · cited 1×
“These studies show compensatory upregulation of postsynaptic GABAA receptors in the very regions associated with downregulation of presynaptic GABAergic markers (Hanada et al., 1987; Benes et al., 1996; Impagnatiello et al., 1998; Volk et al., 2002).”
BackgroundLane, H.-Y., Chang, Y.-C., Liu, Y.-C., Chiu, C.-C., & Tsai, G. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1196 · Cited by 271 · cited 1×
“Furthermore, sarcosine appeared to be more effective in the acutely symptomatic patients (Lane et al., 2005).”
BackgroundHolzman, P. S. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800310049006 · Cited by 269 · cited 2×
“For example, there is an increased prevalence of eye tracking abnormalities in subjects with schizophrenia and their first-degree relatives (Holzman et al., 1988).”
BackgroundHashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267 · cited 1×
“…and reduces positive symptoms in patients with chronic schizophrenia, who are receiving concurrent typical antipsychotic medications (Tsai et al., 1998; Heresco-Levy et al., 2002) and (2) that serum and CSF levels of D-serine are reduced in schizophrenic subjects (Hashimoto et al., 2003, 2005).”
BackgroundStevens, E. R., Esguerra, M., Kim, P. M., Newman, E. A., Snyder, S. H., Zahs, K. R., & Miller, R. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1237052100 · Cited by 267 · cited 1×
“Reduced availability of D-serine would lead to NMDAR hypofunction (Stevens et al., 2003).”
BackgroundVolk, D. W. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.10.1063 · Cited by 265 · cited 1×
“These studies show compensatory upregulation of postsynaptic GABAA receptors in the very regions associated with downregulation of presynaptic GABAergic markers (Hanada et al., 1987; Benes et al., 1996; Impagnatiello et al., 1998; Volk et al., 2002).”
BackgroundCloning, expression, and localization of a rat brain high-affinity glycine transporter.
Guastella, J., Brecha, N., Weigmann, C., Lester, H. A., & Davidson, N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7189 · Cited by 263 · cited 1×
“Guastella et al. (1992) cloned Na+ dependent glycine transporter (GlyT1) from brain and demonstrated that it was inhibited by sarcosine.”
BackgroundHattori, E., Liu, C., Badner, J. A., Bonner, T. I., Christian, S. L., Maheshwari, M., Detera-Wadleigh, S. D., Gibbs, R. A., & Gershon, E. S. (2003) · The American Journal of Human Genetics · doi:10.1086/374822 · Cited by 263 · cited 3×
“…studies have demonstrated an association of G72 with the risk for schizophrenia and two with the risk for bipolar disorder (Chumakov et al., 2002; Hattori et al., 2003; Addington et al., 2004; Chen et al., 2004; Korostishevsky et al., 2004; Schumacher et al., 2004; Wang et al., 2004;…”
BackgroundZafra, F., Gomeza, J., Olivares, L., Aragón, C., & Giménez, C. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb01125.x · Cited by 259 · cited 1×
“The glycine transporter1 (GlyT1), which regulates synaptic glycine, is astrocytic (Zafra et al., 1995).”
BackgroundLewis, D., Volk, D., & Hashimoto, T. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1673-x · Cited by 253 · cited 1×
“…and DNA chip array methods, have confirmed the reduction in the presynaptic markers for GABAergic inter-neurons in subsectors of the hippocampal formation and in the intermediate layers of the prefrontal and cingulate cortex [for reviews, (Benes and Berretta, 2001; Lewis et al., 2004)].”
MethodThe Effects of Clozapine on Alcohol and Drug Use Disorders Among Patients With Schizophrenia
Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033464 · Cited by 253 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundDose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243 · cited 1×
“Goff et al. (1995) used the partial GMS agonist, D-cycloserine, which crosses the blood brain barrier, in an initial dose finding study and observed a U-shaped dose response curve with improvement in negative symptoms and reduction in cognitive impairments at a dose of 50 mg/day.”
MethodSelf-citationElevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
Nilsson, L. K., Linderholm, K. R., Engberg, G., Paulson, L., Blennow, K., Lindström, L. H., Nordin, C., Karanti, A., Persson, P., & Erhardt, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.013 · Cited by 238 · cited 1×
“Kynurenic acid levels are also elevated in the CSF of living patients with schizophrenia (Erhardt et al., 2001; Nilsson et al., 2005).”
BackgroundMiller, C. L., Llenos, I. C., Dulay, J. R., Barillo, M. M., Yolken, R. H., & Weis, S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.015 · Cited by 233
Coyle, J., & Tsai, G. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1709-2 · Cited by 230 · cited 2×
“D-cycloserine, to behave like an antagonist thereby exacerbating negative symptoms and the full agonists, glycine and D-serine, to lack efficacy (Coyle and Tsai, 2004).”
BackgroundSelf-citationChen, L., Muhlhauser, M., & Yang, C. R. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00680.2002 · Cited by 230 · cited 1×
“Chen et al. (2003) showed similar effects of NFPS on NMDAR currents in the acute frontal cortex slice.”
ResultThe long-term potential of LTP
Malenka, R. C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1258 · Cited by 229 · cited 1×
“During the induction of long-term potentiation (LTP), convergent excitatory synapses cause robust synaptic de-polarization, Ca2+ entry through NMDAR and persistent upregulation of AMPAR function (Malenka, 2003).”
BackgroundGlycine Uptake Governs Glycine Site Occupancy at NMDA Receptors of Excitatory Synapses
Berger, A. J., Dieudonné, S., & Ascher, P. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.6.3336 · Cited by 229 · cited 2×
“Aside from the glutamate/NMDA recognition site, a second site on NR1 binds glycine/D-serine (this is termed the glycine modulatory site, GMS; also, the Glycine B Receptor) and must be occupied for glutamate to open the channel (Berger et al., 1998).”
BackgroundHill, J. J., Hashimoto, T., & Lewis, D. A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001792 · Cited by 228
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227 · cited 1×
“And Tsai et al. (1999) showed that the addition of the full agonist D-serine to clozapine responders also had no effect on negative symptoms.”
BackgroundSelf-citationVolk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.256 · Cited by 221 · cited 2×
“sented evidence for the loss of GABAergic chandelier cell terminals (“cartridges”) on pyramidal initial axon segments (Woo et al., 1998; Volk et al., 2001).”
BackgroundJavit, D. C., Steinschneider, M., Schroeder, C. E., Vaughan, H. G., & Arezzo, J. C. (1994) · Brain Research · doi:10.1016/0006-8993(94)91496-6 · Cited by 219 · cited 1×
“Furthermore, his research in monkeys indicates the central role of NMDAR in mismatch negativity paradigms for ERPs (Javitt et al., 1994, 1996).”
BackgroundRegulation of NMDA Receptors by Neuregulin Signaling in Prefrontal Cortex
Gu, Z., Jiang, Q., Fu, A. K. Y., Ip, N. Y., & Yan, Z. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1086-05.2005 · Cited by 213 · cited 1×
“Furthermore, neuregulin directly reduces NMDAR currents in cultured prefrontal cortical neurons (Gu et al., 2005).”
BackgroundGroup II Metabotropic Glutamate Receptors Modulate Extracellular Glutamate in the Nucleus Accumbens
Xi, Z.-X., Baker, D. A., Shen, H., Carson, D. S., & Kalivas, P. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.162 · Cited by 212 · cited 1×
“In addition, G-protein coupled glutamate receptors, the metabotropic receptors, modulate glutamatergic neurotransmission; for instance, presynaptic mGluR3 receptors inhibit the release of glutamate (Xi et al., 2002).”
BackgroundZornberg, G. L., Buka, S. L., & Tsuang, M. T. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.196 · Cited by 207 · cited 1×
“Environmental (primarily, perinatal insults) or epigenetic factors contribute to the phenotype (Zornberg et al., 2000).”
BackgroundSchousboe, A. (2003) · Neurochemical Research · doi:10.1023/a:1022397704922 · Cited by 199 · cited 1×
“The astrocyte is an important participant in glutamatergic neurotransmission (Schousboe, 2003).”
BackgroundAdjunctive high-dose glycine in the treatment of schizophrenia
Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A.-M., Bark, N., Park, M., Lindenmayer, J.-P., Suckow, R., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199 · cited 1×
“The findings with the full agonist glycine have been replicated in two additional clinical trials (Heresco-Levy et al., 1999; Javitt et al., 2001).”
ResultSupport for involvement of neuregulin 1 in schizophrenia pathophysiology
Petryshen, T. L., Middleton, F. A., Kirby, A., Aldinger, K. A., Purcell, S., Tahl, A. R., Morley, C. P., McGann, L., Gentile, K. L., Rockwell, G. N., et al. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001608 · Cited by 197 · cited 1×
“NRG1: The association of the neuregulin gene with the risk for schizophrenia is also particularly robust (Petryshen et al., 2005).”
BackgroundQuartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90687-4 · Cited by 190 · cited 1×
“Furthermore, it causes NMDAR desensitization with chronic administration and loss of cognitive enhancing effects in rodent studies (Quartermain et al., 1994).”
BackgroundCognitive and clinical predictors of success in vocational rehabilitation in schizophrenia
EVANS, J. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.011 · Cited by 190 · cited 1×
“365 0272-4340/06/0700-0365/1 C© 2006 Springer Science+Business Media, Inc. employment (Evans et al., 2004).”
Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype
Tsai, G., Ralph-Williams, R. J., Martina, M., Bergeron, R., Berger-Sweeney, J., Dunham, K. S., Jiang, Z., Caine, S. B., & Coyle, J. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402662101 · Cited by 190 · cited 3×
“Studies of mice with a null mutation of GlyT1 add credence to the hypothesis that NMDAR hypofunction could be mediated through the GMS (Tsai et al., 2004).”
BackgroundSelf-citationKorostishevsky, M., Kaganovich, M., Cholostoy, A., Ashkenazi, M., Ratner, Y., Dahary, D., Bernstein, J., Bening-Abu-Shach, U., Ben-Asher, E., Lancet, D., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.04.006 · Cited by 186 · cited 1×
“…schizophrenia and two with the risk for bipolar disorder (Chumakov et al., 2002; Hattori et al., 2003; Addington et al., 2004; Chen et al., 2004; Korostishevsky et al., 2004; Schumacher et al., 2004; Wang et al., 2004; Korostishevsky et al., 2006), One study reported increased expression of G72…”
BackgroundD-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182 · cited 1×
“However, Goff and his collaborators carried out two independent studies with D-cycloserine in clozapine responders and observed a significant exacerbation of negative symptoms (Goff et al., 1996; Goff et al., 1999).”
ResultSelf-citationGoff, D. C., Henderson, D. C., Evins, A. E., & Amico, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178 · cited 3×
“In a large parallel placebo-controlled trial, Goff et al. (1999) replicated the effects of D-cycloserine on negative symptoms in chronic schizophrenics receiving typical antipsychotics but not the cognitive effects (Goff et al., 1999).”
BackgroundResultEndogenous kynurenic acid disrupts prepulse inhibition
Erhardt, S., Schwieler, L., Emanuelsson, C., & Geyer, M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.006 · Cited by 178 · cited 1×
“Erhardt et al. (2004) have shown that elevation of endogenous brain kynurenic acid in rats disrupts the prepulse inhibition of the acoustic startle reflex, a sensory gating abnormality common in schizophrenia, and that this disruption can be reversed by treatment with clozapine.”
BackgroundCerebral ventricular change over the first 10 years after the onset of schizophrenia
DeLisi, L. E., Sakuma, M., Maurizio, A. M., Relja, M., & Hoff, A. L. (2004) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2003.08.004 · Cited by 177 · cited 1×
“Prospective studies indicate that reduced cortical volume is present at first episode but can progress during the first several years of illness (DeLisi et al., 2004; Gogtay et al., 2004; Mittelman et al., 2003).”
Backgroundβ-dystrobrevin, a member of the dystrophin-related protein family
Blake, D. J., Nawrotzki, R., Loh, N. Y., Górecki, D. C., & Davies, K. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.241 · Cited by 177 · cited 5×
“These include COMT (Goldberg et al., 2003), Dysbindin (Blake et al., 1998), Neuregulin (Falls, 2003), Regulator of G-protein Signaling 4 (RGS4; Williams et al., 2004), Disrupted In Schizophrenia 1 (DISC1; Cannon et al., 2005), metabotrophic glutamate receptor3 (GRM3; Egan et al., 2004) and G-72…”
BackgroundInfluentialGenetic variation in DTNBP1 influences general cognitive ability
Burdick, K. E., Lencz, T., Funke, B., Finn, C. T., Szeszko, P. R., Kane, J. M., Kucherlapati, R., & Malhotra, A. K. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi481 · Cited by 173
Watson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., & Lanthorn, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90745-w · Cited by 172 · cited 1×
“Dcycloserine is not the optimal agent for testing the GMS strategy because it is a partial agonist with 50% of the efficacy of glycine (Watson et al., 1990).”
BackgroundPlacebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172 · cited 1×
“Furthermore, they showed that the addition of the full agonist, glycine, (Evins et al., 2000) had no effects on negative symptoms in clozapine responders.”
BackgroundKinney, G. G., Sur, C., Burno, M., Mallorga, P. J., Williams, J. B., Figueroa, D. J., Wittmann, M., Lemaire, W., & Conn, P. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07586.2003 · Cited by 172 · cited 1×
“Kinney et al. (2003) have extended the studies in vivo, demonstrating not only increased NMDAR currents in the dentate gyrus after systemic treatment with NFPS but also increased LTP.”
BackgroundDopamine receptors, neuroleptics, and schizophrenia
(1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.4.460 · Cited by 169 · cited 2×
“All current antipsychotics exert their effects primarily by blocking D2 dopamine receptors (Snyder, 1981; Seeman, 2002).”
BackgroundHeresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167 · cited 4×
“D-serine has been replicated in a placebo-controlled trial in chronic schizophrenic subjects receiving concurrent antipsychotics carried out in Israel (Heresco-Levy et al., 2002).”
BackgroundInfluentialZimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., & Green, A. I. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00016 · Cited by 163 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundGogtay, N., Sporn, A. L., CLASEN, L. S., Nugent, T. F., GREENSTEIN, D. K., Nicolson, R., Giedd, J. N., Lenane, M., Gochman, P., Evans, A. C., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.17 · Cited by 160 · cited 1×
“Prospective studies indicate that reduced cortical volume is present at first episode but can progress during the first several years of illness (DeLisi et al., 2004; Gogtay et al., 2004; Mittelman et al., 2003).”
BackgroundSelemon, L. D., Mrzljak, J., Kleinman, J. E., Herman, M. M., & Goldman, P. S. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.69 · Cited by 158 · cited 1×
“As there is little indication of neuronal degeneration in these regions, these results suggest compromised glutamatergic function (Selemon et al., 2003).”
BackgroundKirov, G., O'Donovan, M. C., & Owen, M. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24759 · Cited by 152 · cited 4×
“However, it does not appear to be a disorder of Mendellian genetics but rather of complex genetics, in which multiple genes of small effect interact to cause the phenotype (Kirov et al., 2005).”
BackgroundInfluentialYamasue, H., Iwanami, A., Hirayasu, Y., Yamada, H., Abe, O., Kuroki, N., Fukuda, R., Tsujii, K., Aoki, S., Ohtomo, K., et al. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.05.004 · Cited by 149 · cited 2×
“…studies over the last two decades have provided compelling evidence that schizophrenia is associated with enlargement of the lateral ventricles and the loss of volume in the prefrontal cortex, the temporal cortex, the hippocampus, the amygdala and the thalamus (Heckers, 2001; Yamasue et al., 2004).”
BackgroundEffect of Phencyclidine in Chronic Schizophrenics
Itil, T. M., Keskiner, A., Kiremitci, N., & Holden, J. (1967) · Canadian Psychiatric Association Journal · doi:10.1177/070674376701200217 · Cited by 148 · cited 2×
“that was difficult to distinguish from schizophrenia (Luby et al., 1959; Itil et al., 1967).”
BackgroundSupport for RGS4 as a susceptibility gene for schizophrenia
Williams, N. M., Preece, A. C., Spurlock, G., Norton, N., Williams, H. J., McCreadie, R. G., Buckland, P. R., Sharkey, V., Chowdari, K. V., Zammit, S., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.002 · Cited by 145 · cited 4×
“ing candidate genes for schizophrenia (Williams et al., 2004).”
BackgroundInfluentialAddington, A. M., Gornick, M. C., Sporn, A. L., Gogtay, N., GREENSTEIN, D. K., Lenane, M., Gochman, P., Baker, N., Balkissoon, R., Vakkalanka, R., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.024 · Cited by 143 · cited 1×
“…an association of G72 with the risk for schizophrenia and two with the risk for bipolar disorder (Chumakov et al., 2002; Hattori et al., 2003; Addington et al., 2004; Chen et al., 2004; Korostishevsky et al., 2004; Schumacher et al., 2004; Wang et al., 2004; Korostishevsky et al., 2006), One…”
BackgroundLi, Q., Clark, S., Lewis, D. V., & Wilson, W. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03070.2002 · Cited by 142 · cited 1×
“Li et al. (2002) have shown that limbic GABAergic inter-neurons are more sensitive to the dissociative anaesthetic MK801 than the adjacent the pyramidal neurons.”
Background[3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics
Hanada, S., Mita, T., Nishino, N., & Tanaka, C. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90341-9 · Cited by 140 · cited 1×
“These studies show compensatory upregulation of postsynaptic GABAA receptors in the very regions associated with downregulation of presynaptic GABAergic markers (Hanada et al., 1987; Benes et al., 1996; Impagnatiello et al., 1998; Volk et al., 2002).”
BackgroundJavitt, D. C., Duncan, L., Balla, A., & Sershen, H. W. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001552 · Cited by 138 · cited 1×
“Javitt et al. (2005) has proposed that the effects of clozapine on negative symptoms results from inhibition of a novel glycine transporter.”
BackgroundChen, Y. S., Akula, N., Detera‐Wadleigh, S. D., Schulze, T. G., Thomas, J., Potash, J. B., DePaulo, J. R., McInnis, M. G., Cox, N. J., & McMahon, F. J. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001453 · Cited by 128
Ionotropic Glutamate Receptors as Therapeutic Targets in Schizophrenia
Coyle, J. T., Tsai, G. E., & GOFF, D. C. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606212 · Cited by 125 · cited 2×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSelf-citationNMDA Receptor Pharmacology: Perspectives from Molecular Biology
Lynch, D. R., & Guttmann, R. P. (2001) · Current Drug Targets · doi:10.2174/1389450013348434 · Cited by 124 · cited 2×
“The NMDA receptor is a tetramer containing two subunits; NR1, which is required for channel function, and NR2A-D, which affect the biophysical and pharmacologic characteristics of the NMDAR (Lynch and Guttmann, 2001).”
BackgroundGOFF, D. C., Herz, L. R., Posever, T. A., Shih, V. E., Tsai, G. E., Henderson, D. C., Freudenreich, O., Evins, A. E., Yovel, I., Zhang, H., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2032-2 · Cited by 116 · cited 1×
“On the negative side, Goff et al. (2005) recently reported that in a 6-month trial 50 mg/day of D-cycloserine did not separate from placebo in any primary out-come measures including negative symptoms.”
BackgroundGlutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system
Berger, U. V., Luthi‐Carter, R., Passani, L. A., Elkabes, S., Black, I. B., Konradi, C. L., & Coyle, J. T. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991206)415:1<52::aid-cne4>3.0.co;2-k · Cited by 114 · cited 1×
“GCPII, which degrades NAAG, is concentrated in the astrocyte end-feet (Berger et al., 1999).”
BackgroundSelf-citationCOYLE, J. T., & Schwarcz, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.90 · Cited by 111 · cited 2×
“Two decades of research on N-acetyl aspartyl glutamate has illuminated the negative modulation of glutamatergic neurotransmission and the unexpected central role of glia in NMDAR function (Coyle and Schwarcz, 2000).”
BackgroundSelf-citationAuditory P300 in high-risk, recent-onset and chronic schizophrenia
van der Stelt, O., Lieberman, J. A., & Belger, A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.024 · Cited by 110 · cited 1×
“Smaller P 300 waves induced by auditory or visual stimuli correlated with duration of illness (van der Stelt et al., 2005).”
BackgroundMitelman, S. A., Shihabuddin, L., Brickman, A. M., Hazlett, E. A., & Buchsbaum, M. S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2154 · Cited by 110 · cited 1×
“Prospective studies indicate that reduced cortical volume is present at first episode but can progress during the first several years of illness (DeLisi et al., 2004; Gogtay et al., 2004; Mittelman et al., 2003).”
BackgroundThe N –methyl D–aspartate receptor glycine site and D–serine metabolism: an evolutionary perspective
Schell, M. J. (2004) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2003.1399 · Cited by 109 · cited 1×
“Both serine racemase, that synthesizes D-serine (SR), and D-amino acid oxidase (DAAO), which catabolizes D-serine, are localized to astrocytes (Schell, 2004; Wolosker et al., 1999; Kirkpatrick et al., 2001; Harrison and Weinberger, 2004).”
BackgroundAssociation of G72/G30 with schizophrenia in the Chinese population
Wang, X., He, G., Gu, N., Yang, J., Tang, J. X., Chen, Q., Liu, X., Shen, Y., Qian, X., Lin, W., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.119 · Cited by 101 · cited 1×
“…disorder (Chumakov et al., 2002; Hattori et al., 2003; Addington et al., 2004; Chen et al., 2004; Korostishevsky et al., 2004; Schumacher et al., 2004; Wang et al., 2004; Korostishevsky et al., 2006), One study reported increased expression of G72 in prefrontal cortex (Hattori et al., 2003).”
BackgroundReversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 99 · cited 1×
“Preclinical studies in rat indicated that high doses of the full GMS agonist, glycine, reversed the behavioral effects of NMDR antagonists (Javitt et al., 1999).”
BackgroundRadant, A. D., Bowdle, T. A., Cowley, D. S., Kharasch, E. D., & Roy-Byrne, P. P. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00030-x · Cited by 97 · cited 1×
“Low dose ketamine mimics in controls the abnormal saccades observed in schizophrenia (Radant et al., 1998).”
BackgroundComparative genome‐ and proteome analysis of cerebral cortex from MK‐801‐treated rats
Paulson, L., Martin, P., Persson, A. I., Nilsson, C. L., Ljung, E., Brinkmalm, A., Eriksson, P. S., Blennow, K., & Davidsson, P. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10509 · Cited by 97 · cited 1×
“Paulson et al. (2003) reported that chronic treatment with MK801 resulted in downregulation in the expression of GAD and GAT in the frontal cortex of rats similar to the reductions observed in schizophrenia.”
ResultAuer, D. P., Wilke, M., Grabner, A., Heidenreich, J. O., Bronisch, T., & Wetter, T. C. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00155-4 · Cited by 96 · cited 1×
“MRS studies have repeatedly revealed slight but significant reductions in the levels of NAA in prefrontal cortex (Sigmundsson et al., 2003), temporal lobe (Deicken et al., 1999) and thalamus (Auer et al., 2001).”
BackgroundLeiderman, E. A., Zylberman, I., Zukin, S. R., Cooper, T. B., & Javitt, D. C. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00585-4 · Cited by 92 · cited 1×
“Leiderman et al. (1996) used high dose (30–60 g/day) glycine and showed significant improvement in negative symptoms and cognitive impairments in chronic schizophrenic subjects receiving concurrent typical antipsychotics.”
BackgroundGornick, M. C., Addington, A. M., Sporn, A. L., Gogtay, N., GREENSTEIN, D. K., Lenane, M., Gochman, P., Ordóñez, A. E., Balkissoon, R., Vakkalanka, R., et al. (2005) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-0028-3 · Cited by 91
Elston, G. N., Tweedale, R., & Rosa, M. G. P. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991206)415:1<144::aid-cne10>3.0.co;2-7 · Cited by 90
Self-citationSigmundsson, T., Maier, M., Toone, B., Williams, S., Simmons, A., Greenwood, K., & Ron, M. A. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00533-9 · Cited by 88 · cited 1×
“MRS studies have repeatedly revealed slight but significant reductions in the levels of NAA in prefrontal cortex (Sigmundsson et al., 2003), temporal lobe (Deicken et al., 1999) and thalamus (Auer et al., 2001).”
BackgroundM50 sensory gating predicts negative symptoms in schizophrenia
Thoma, R. J., Hanlon, F. M., Moses, S. N., Ricker, D., Huang, M., Edgar, C. J., Irwin, J., Torres, F., Weisend, M. P., Adler, L. E., et al. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.07.001 · Cited by 84 · cited 1×
“For example, Thoma et al. (2005) showed a correlation between event related field at 50 ms in the right hemisphere and negative symptoms.”
BackgroundCNS region‐specific regulation of glial glutamate transporter expression
Schlüter, K., Figiel, M., Rozyczka, J., & Engele, J. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02130.x · Cited by 74 · cited 1×
“The two glutamate transporters responsible for inactivating synaptic glutamate and protecting against excitotoxicity, EAAT1 and 2, are expressed by the astrocytes (Schluter et al., 2002).”
BackgroundSnyder, S. H. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.7.992 · Cited by 69
Bergeron, R., Coyle, J. T., Tsai, G., & Greene, R. W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300559 · Cited by 65 · cited 3×
“And NAAG is a glycine reversible antagonist of the NMDAR (Grunze et al., 1996; Bergeron et al., 2005).”
BackgroundSelf-citationIdentification and analysis of plasticity-induced late-response genes
Hong, S. J., Li, H., Becker, K. G., Dawson, V. L., & Dawson, T. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305170101 · Cited by 64 · cited 2×
“The open NMDAR allows the influx of Ca2+, which activates a cascade of enzymes that affect the biochemistry of local synaptic plasticity and the processes of gene expression (Hong et al., 2004).”
BackgroundReduced hippocampal N-acetylaspartate without volume loss in schizophrenia
Deicken, R. F., Pegues, M., & Amend, D. L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00173-x · Cited by 61 · cited 2×
“, 2003), temporal lobe (Deicken et al., 1999) and thalamus (Auer et al.”
BackgroundLand, C., & Riccio, D. C. (1999) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1998.3897 · Cited by 61 · cited 2×
“The GMS partial agonist, D-cycloserine, with acute administration enhanced performance of memory tasks in rats (Land and Riccio, 1999; Andersen et al., 2002).”
BackgroundBerretta, S., Lange, N., Bhattacharyya, S., Sebro, R., Garces, J., & Benes, F. M. (2004) · Hippocampus · doi:10.1002/hipo.20002 · Cited by 61 · cited 2×
“and receptor expression in the hippocampus in a manner virtually identical to the postmortem findings in schizophrenia (Berretta et al., 2004; Gisabella et al., 2005).”
ResultKorostishevsky, M., Kremer, I., Kaganovich, M., Cholostoy, A., Murad, I., Muhaheed, M., Bannoura, I., Rietschel, M., Dobrusin, M., Bening-Abu-Shach, U., et al. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30212 · Cited by 58 · cited 1×
“…disorder (Chumakov et al., 2002; Hattori et al., 2003; Addington et al., 2004; Chen et al., 2004; Korostishevsky et al., 2004; Schumacher et al., 2004; Wang et al., 2004; Korostishevsky et al., 2006), One study reported increased expression of G72 in prefrontal cortex (Hattori et al., 2003).”
BackgroundRegulation of synaptic plasticity in a schizophrenia model
Gisabella, B., Bolshakov, V. Y., & Benes, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506034102 · Cited by 58 · cited 2×
“and receptor expression in the hippocampus in a manner virtually identical to the postmortem findings in schizophrenia (Berretta et al., 2004; Gisabella et al., 2005).”
ResultNinan, I., Jardemark, K. E., & Wang, R. Y. (2003) · Synapse · doi:10.1002/syn.10189 · Cited by 58 · cited 1×
“Enhanced NMDAR function with chronic clozapine treatment has been demonstrated in rat frontal cortex (Ninan et al., 2003).”
BackgroundHashimoto, A., & Chiba, Y. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.05.036 · Cited by 52 · cited 2×
“D-serine crosses the blood-brain barrier three times better than glycine (Oldendorf, 1971), has a threefold greater potency at NMDAR than glycine (Matsui et al., 1995) and exhibits a long half-life in cortex upon peripheral administration (Hashimoto and Chiba, 2004).”
BackgroundPassani, L. A., Vonsattel, J. P., & Coyle, J. T. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00784-1 · Cited by 50 · cited 1×
“…presynaptic terminals of pyramidal cells in the primate cortex and limbic system also have high concentrations of N-acetyl-aspartyl glutamate (NAAG), which is co-localized and released with glutamate (Passani et al., 1997; Bergeron et al., 2005), and which modulates glutamatergic neurotransmission.”
BackgroundSelf-citationUptake of Radiolabeled Essential Amino Acids by Brain Following Arterial Injection
Oldendorf, W. H. (1971) · Experimental Biology and Medicine · doi:10.3181/00379727-136-35270 · Cited by 48 · cited 1×
“D-serine crosses the blood-brain barrier three times better than glycine (Oldendorf, 1971), has a threefold greater potency at NMDAR than glycine (Matsui et al., 1995) and exhibits a long half-life in cortex upon peripheral administration (Hashimoto and Chiba, 2004).”
BackgroundYurgelun-Todd, D. A., Coyle, J. T., Gruber, S. A., Renshaw, P. F., Silveri, M. M., AMICO, E. T., Cohen, B. M., & GOFF, D. C. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.11.006 · Cited by 47 · cited 1×
“Yurgelun-Todd et al. (2005) have found evidence supporting these postmortem findings with in vivo MRS, which revealed a significant reduction in GABA levels in the prefrontal cortex in schizophrenia.”
ResultSelf-citationBischofberger, J., & Schild, D. (1996) · Journal of Neurophysiology · doi:10.1152/jn.1996.76.3.2089 · Cited by 45 · cited 2×
“NAAG is a potent and specific agonist at the mGluR3 receptor (Wroblewska et al., 1997; Bischofberger and Schild, 1996), which gene has been associated with the risk for schizophrenia (Egan et al., 2004).”
BackgroundLladó, J., Calderó, J., Ribera, J., Tarabal, O., Oppenheim, R. W., & Esquerda, J. E. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-24-10803.1999 · Cited by 44 · cited 1×
“More prolonged activation of NMDAR can cause spine proliferation as well as have trophic effects on postsynaptic neurons (Llado et al., 1999).”
BackgroundEffects of scopolamine and d-cycloserine on non-spatial reference memory in rats
Andersen, J. M., Lindberg, V., & Myhrer, T. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00318-7 · Cited by 40 · cited 2×
“The GMS partial agonist, D-cycloserine, with acute administration enhanced performance of memory tasks in rats (Land and Riccio, 1999; Andersen et al., 2002).”
BackgroundHashimoto, A. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03466-2 · Cited by 34 · cited 2×
“DAAO appears to be the critcal determinant of D-serine levels as its activity correlates inversely with D-serine levels both regionally and developmently (Hashimoto, 2002).”
BackgroundAlzheimer�s Disease, Molecular Biology and the Future of Rational Neuropsychotropic Drug Development
Coyle, J. T. (1998) · KARGER eBooks · doi:10.1159/000061367 · Cited by 1 · cited 2×
“…IV, alpha-anti-chymotrypsin and environmental factors, (education, head trauma, antioxidant exposure) interact to result in the neuropathology (deposition of the Aβ peptide in senile plaques), the selective neuronal vulnerability and the symptomatic manifestations of the disorder (Coyle, 1998).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319:1281–1286. · DOI
Cited by
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Dendritic spine pathology in neuropsychiatric disorders
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2741 · Cited by 1,523
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophreni”
BackgroundCorrell, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Ross, C. A., Margolis, R. L., Reading, S. A. J., Pletnikov, M., & Coyle, J. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.015 · Cited by 686
“Evidence for a role of glutamate in schizophrenia also originated from pharmacology (Coyle, 2006).”
Self-citation
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.